FOXA2 controls the anti-oxidant response in FH-deficient cells

Cell Rep. 2023 Jul 25;42(7):112751. doi: 10.1016/j.celrep.2023.112751. Epub 2023 Jul 4.

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a cancer syndrome caused by inactivating germline mutations in fumarate hydratase (FH) and subsequent accumulation of fumarate. Fumarate accumulation leads to profound epigenetic changes and the activation of an anti-oxidant response via nuclear translocation of the transcription factor NRF2. The extent to which chromatin remodeling shapes this anti-oxidant response is currently unknown. Here, we explored the effects of FH loss on the chromatin landscape to identify transcription factor networks involved in the remodeled chromatin landscape of FH-deficient cells. We identify FOXA2 as a key transcription factor that regulates anti-oxidant response genes and subsequent metabolic rewiring cooperating without direct interaction with the anti-oxidant regulator NRF2. The identification of FOXA2 as an anti-oxidant regulator provides additional insights into the molecular mechanisms behind cell responses to fumarate accumulation and potentially provides further avenues for therapeutic intervention for HLRCC.

Keywords: CP: Cancer; CP: Molecular biology; FOXA2; NRF2; anti-oxidant response; fumarate hydratase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants
  • Carcinoma, Renal Cell* / genetics
  • Chromatin
  • Female
  • Fumarate Hydratase / genetics
  • Hepatocyte Nuclear Factor 3-beta / genetics
  • Humans
  • Kidney Neoplasms* / genetics
  • Leiomyomatosis* / genetics
  • NF-E2-Related Factor 2 / genetics
  • Neoplastic Syndromes, Hereditary* / genetics
  • Skin Neoplasms* / genetics
  • Uterine Neoplasms* / genetics

Substances

  • Fumarate Hydratase
  • Antioxidants
  • NF-E2-Related Factor 2
  • Chromatin
  • FOXA2 protein, human
  • Hepatocyte Nuclear Factor 3-beta

Supplementary concepts

  • Hereditary leiomyomatosis and renal cell cancer